UPDATE: Goldman Sachs initiates on Synageva Following Positive Phase II Data On Sebelipase
November 15, 2013 at 07:47 AM EST
In a report published Thursday, Goldman Sachs analyst Navdeep Singh initiated a Buy rating on Synageva BioPharma (NASDAQ: GEVA ) and initiated a price target of $72.00. In the report, Goldman Sachs says "We initiate coverage of Synageva with a Buy rating and a 12m target of $72. Synageva develops drugs
